By Karen Roman Biopharmaceutical company ReAlta Life Sciences said it appointed Andrew Miller, Ph.D., to its Board of Directors. Dr. Miller is the founder of Karuna Therapeutics, acquired by Bristol Myers Squibb for $14 billion in 2024, the company declared....

By Daniella Parra March Biosciences was granted an orphan drug designation from the FDA to MB-105, its CD5-targeted CAR-T cell therapy, which has shown promising safety and efficacy in Phase 1 trials, with a 44% response rate in TCL patients,...

By Daniella Parra Lisata Therapeutics said results from Cohort A of its Phase 2 ASCEND trial showed complete responses in 6.2% of certepetide-treated patients, compared to 0% in the placebo group. The company said it evaluated its investigational drug certepetide...

By Daniella Parra Araris Biotech AG, a Swiss oncology biotech firm, has partnered with Chugai Pharmaceutical to develop advanced antibody-drug conjugates (ADCs) using Araris’ AraLinQ platform, the company said. The collaboration aims to create ADCs in cancer treatments by incorporating...

By Daniella Parra MOBILion Systems, Inc. said its SLIM (Structures for Lossless Ion Manipulation) platform, developed by Dr. Richard D. Smith in 2014, has been featured in 100 peer-reviewed publications. The company said SLIM has advanced fields such as drug...

By Karen Roman Oculis Holding AG (Nasdaq: OCS) said Phase 2 of its neuroprotective candidate OCS-05 met key endpoints of safety and efficacy, highlighting its potential to treat acute optic neuritis. Oculis also said it received the Investigational New Drug...

By Karen Roman March Biosciences said it elected Peter Olagunju as chair of its Board of Directors, following a $28.4 million Series A financing the company secured for its lead cancer therapy. Mr. Olagunju has over 20 years of experience...

By Daniella Parra MOBILion Systems said it partnered with Dr. Oliver Schmitz of the University of Duisburg-Essen, known for his expertise in multidimensional chromatography and ion source development, to integrate its technology. This collaboration focuses on advancing multiomics applications, particularly...

By Karen Roman Agendia, Inc. said it will present data to assess treatment decisions on patients with early-stage breast cancer at the San Antonio Breast Cancer Symposium 2024. The studies will show how genomic testing can predict patients’ response to chemotherapy,...

By Karen Roman Agendia, Inc. said it will present MammaPrint’s ability to predict chemotherapy benefit in patients with early-stage breast cancer at the San Antonio Breast Cancer Symposium 2024. “This study highlights the ability of MammaPrint to provide a comprehensive...